Description: Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People's Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People's Republic of China.
Home Page: www.genscript.com
Jiangning Science Park
Nanjing,
211100
China
Phone:
86 25 5889 7288
Officers
| Name | Title |
|---|---|
| Mr. Jiange Meng | Executive Chairman |
| Ms. Weihui Shao | CEO & COO |
| Ms. Ye Wang M.S. | Co-Founder, President & Executive Director |
| Dr. Luquan Wang | Co-Founder & Non-Executive Director |
| Dr. Fangliang Zhang EMBA, Ph.D. | Co-Founder & Executive Director |
| Dr. Li Zhu Ph.D. | Chief Strategy Officer & Executive Director |
| Mr. Shiniu Wei | Chief Financial Officer |
| Ms. Aylin Kosova Bilgin | Chief Marketing Officer for GenScript Life Science Group |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 94.3396 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.4962 |
| Price-to-Sales TTM: | 2.852 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7284 |